HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ceccarelli, C. Articles by Pinchera, A. Search for Related Content PubMed PubMed Citation Articles by Ceccarelli, C. Articles by Pinchera, A.

Radiation Dose to the Testes after ¹³¹I Therapy for Ablation of Postsurgical Thyroid Remnants in Patients with Differentiated Thyroid Cancer

Institute of Endocrinology, University of Pisa, Pisa
Institute for Radiation Protection of Italian Agency for New Technologies, Energy and the Environment, Bologna, Italy

Correspondence: For correspondence or reprints contact: Claudia Ceccarelli, MD, Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, University of Pisa, Ospedale Cisanello, Via Paradisa 2, 56122 Pisa, Italy.

ABSTRACT

Radioiodine-131 is used indifferentiated thyroid cancer (DTC) for ablation of postsurgical thyroid remnants and destruction of metastases. The question may be raised of whether ¹³¹I treatment of DTC in male patients may give an irradiation dose to the testes that could impair fertility. Few data in the literature concern the dose absorbed by the testes after ¹³¹I therapy for DTC. Because ¹³¹I kinetics maybe altered by the hypothyroid condition commonly present at the time of treatment and by the radioiodinated iodoproteins released by the damaged thyroid tissue, the dose values reported in the International Commission on Radiological Protection (ICRP) tables for euthyroid men may not be appropriate. To clarify this problem, three male subjects undergoing ¹³¹I therapy for ablation of thyroid remnants shortly after thyroidectomy for DTC were studied. Methods: The mean administered activity was 1256 MBq, and the duration of the study was 2wk. The gamma dose was measured by thermoluminescent dosimeters (TLDs) applied to the lower poles of the testes. Correction factors were calculated for the distance of the TLD from the center of the testes and for attenuation by the testes of the rays reaching the TLD. After correction, the gamma dose to the testes ranged from 21 to 29 mGy. The gamma dose calculated by the Medical Internal Radiation Dose (MIRD) method from blood and urine samples was similar (18–20 mGy) to that measured by TLDs. The beta dose was estimated by the MIRD method from blood activity and testicular volume and ranged between 14 and 31 mGy. Results: The total (beta and gamma) doses to testes were 30, 33 and 43 µGy/MBq in the three subjects. Conclusion: These values are close to those derived from the ICRP tables (26–37 µGy/MBq ¹³¹I) for euthyroid subjects. The present data indicate that significant irradiation is delivered to the testes after the administration of the ¹³¹I abiative dose to thyroidectomized patients. The relevance of the radiation absorbed by testes on fertility remains to be established.

Key Words: radiation dose • testes dose • ¹³¹I therapy • differentiated thyroid cancer

This article has been cited by other articles:

				P. W. Rosario, M. A. R. Borges, and S. Purisch Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity J. Nucl. Med., November 1, 2008; 49(11): 1776 - 1782. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, C. Harmer, G. G Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, E. Limbert, P. Lind, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur. J. Endocrinol., November 1, 2005; 153(5): 651 - 659. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]